Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07164313 · ClinicalTrials.gov registry record · Phase 1
A Study of ZW251 in Participants With Advanced Solid Tumors
A Phase 1 study of Hepatocellular Carcinoma, sponsored by Zymeworks BC.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07164313 is a Phase 1 study of Hepatocellular Carcinoma that is actively recruiting participants, run by Zymeworks BC. The registered enrollment target is 100 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT07164313, a Phase 1 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Zymeworks BC.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC).
Conditions Studied
Interventions
- DRUG ZW251
Study Locations (20)
Other
- START - Dublin Mater Misericordiae University Hospital (MMUH) - Dublin
- National Cancer Center East - Kashiwa
- Kyoto University Hospital - Kyoto
- Kansai Medical University Hospital - Osaka
- National Cancer Center Hospital - Tokyo
- START Lisboa a - Unidade de Ensaios ClÃnicos - Hospital de Santa Maria - Lisbon
- Hospital Universitario Vall d'Hebron - Barcelona
- START Barcelona - Barcelona
- START - Rioja Hospital Universitario San Pedro - Logroño
- START Madrid Hospital Universitario Fundacion Jimenez Diaz - Madrid
- START Madrid Hospital Universitario HM Sanchinarro - CIOCC - Madrid
- NEXT Oncology Madrid - Madrid
- National Taiwan University Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
Texas
- MD Anderson Cancer Center - Houston
- START San Antonio - San Antonio
California
- UCSF Comprehensive Cancer Center - San Francisco
Kentucky
- Norton Cancer Institute - Louisville
Michigan
- START Midwest - Grand Rapids
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-21 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07164313
The ClinicalTrials.gov registry entry for NCT07164313 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (61% lower). The listed sponsor is Zymeworks BC, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ZW251 is the first listed.
NCT07164313 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT07164313 about?
NCT07164313 is a clinical study titled "A Study of ZW251 in Participants With Advanced Solid Tumors". The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC).
What is the current status of trial NCT07164313?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-10-21. Estimated completion is 2028-05.
What conditions does trial NCT07164313 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT07164313?
The interventions under investigation include: ZW251 (DRUG).
Who is sponsoring clinical trial NCT07164313?
This trial is sponsored by Zymeworks BC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07164313 being conducted?
This trial has 20 study locations across California, Kentucky, Michigan, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.